Semaglutide (CAS No: 910463-68-2) belongs to the class of GLP-1 receptor agonists and is used both as an antidiabetic for treating type 2 diabetes and as an anti-obesity medication for long-term weight management. Developed by Novo Nordisk in 2012, its compound patent will expire in 2026.

Semaglutide is highly popular due to its effective dual function in treating diabetes and aiding weight loss, with minimal side effects and advanced technology.

Advanced Production Techniques:

Supported by robust technical expertise, Sinoway offers semaglutide produced through both recombinant protease (biological method, similar to the original) and peptide synthesis methods. We also provide key intermediates for research and development purposes without infringing on existing patents.

Certifications and Documentation:

We hold Medicine Production Licenses, comply with GMP (Good Manufacturing Practice) standards, and have Drug Master Files (DMF).

Highlights:

1. High Quality:
   • Biochemical method production: Content 85.0%~102.0% (on dried basis), Biological activity 70%~130%.
   • Polypeptide synthesis production: Assay 95.0%~105.0%, S, impurity not more than 0.1%. (For more details, refer to COAs)
   • Production adheres to GMP and ICH guidelines.
2. Competitive Pricing:
   • Significantly lower than the original product.
3. Availability of Key Intermediates:
• High-quality intermediates available at competitive prices for each production stage

We Sinoway could supply the following Semaglutide Intermediates with high purity and competitive price: